China’s pharmaceutical sector is undergoing a pivotal regulatory shift with the mandated elimination of ‘not yet clear’ labels on Traditional Chinese Medicine (TCM) safety information by 2030. This move, driven by the 2023 Special Provisions for Traditional Chinese Medicine Registration Management, aims to modernize a $150 billion industry burdened by historical ambiguity. The policy requires holders of over 57,000 TCM approval codes to replace vague terms like “adverse reactions not yet clear” with concrete data or forfeit their licenses. This will likely purge the market of dormant “zombie approvals,” concentrate market share among compliant firms, and reduce systemic risk for investors. Contrary to fears of massive new clinical trial costs, the revision process is primarily data-driven, leveraging existing adverse reaction monitoring and historical literature, with manageable compliance expenses. The 2030 deadline represents a fundamental market restructuring, enhancing transparency and creating clear winners and losers based on regulatory preparedness and R&D capability.
The 2030 Deadline: How China’s TCM Labeling Overhaul Will Reshape a $150 Billion Market
